Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Pharmacopsychiatry|January 9, 2001
Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertralineE Spina, A Avenoso, M Salemi, et al.
Biochemical Pharmacology|July 15, 1985
Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomesC von Bahr, E Spina, C Birgersson, et al.
British Journal of Clinical Pharmacology|March 1, 1997
Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjectsE Spina, A Avenoso, G M Campo, et al.
British Journal of Clinical Pharmacology|October 27, 2001
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African populationM G Scordo, E Aklillu, U Yasar, et al.
Therapeutic Drug Monitoring|June 1, 1993
Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjectsE Spina, A M Pollicino, A Avenoso, et al.
Clinical Pharmacology and Therapeutics|November 1, 1984
Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomesE Spina, C Birgersson, C von Bahr, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|September 1, 1994
Iron status in schizophrenic patients with acute neuroleptic-induced dystonic reactionsE Spina, M Ancione, A E Di Rosa, et al.
Pharmacological Research|January 1, 1992
Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patientsE Spina, G M Campo, S Calandra, et al.
Epilepsia|May 1, 1990
Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic studyF Pisani, M Caputo, A Fazio, et al.
European Journal of Clinical Pharmacology|February 24, 2001
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patientsM G Scordo, E Spina, P Romeo, et al.
Pageof 10